Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

European Journal of Pharmacology

Volumn 430, Issue 2-3, 2001, Pages 341-349

  Bymaster, Frank P ^a   Falcone, Julie F ^a   Bauzon, Delbert ^a   Kennedy, John S ^a   Schenck, Kathryn ^a   DeLapp, Neil W ^a   Cohen, Marlene L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

5 HT3 receptor; 5 HT6 receptor; Olanzapine; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

CLOZAPINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; QUETIAPINE; RADIOLIGAND; RISPERIDONE; SEROTONIN 3 AGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 6 RECEPTOR; SULFUR 35; ZIPRASIDONE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; HUMAN CELL; ILEUM; KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SMOOTH MUSCLE CONTRACTION;

ANIMALS; BENZODIAZEPINES; BINDING, COMPETITIVE; CLOZAPINE; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUINEA PIGS; HALOPERIDOL; HELA CELLS; HUMANS; ILEUM; INDOLES; LYSERGIC ACID; MUSCLE CONTRACTION; ONDANSETRON; PIRENZEPINE; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; RISPERIDONE; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SULFUR RADIOISOTOPES; TRITIUM;

EID: 0035798393     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01399-1     Document Type: Article

References (65)

1. Tardive dyskinesia as a result of long-term prochlorperazine use
2. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double blind olanzapine trial
3. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers
4. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons
5. 6 receptors stably expressed in HEK293 cells
6. 6 receptors in nigro-striatal function in rodents
7. 6 receptors as emerging targets for drug discovery
8. 3 receptors in three isolated preparations derived from guinea pig tissues
9. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptor subtypes in intact clonal CHO cells in physiological medium
10. Radioreceptor binding profile of the atypical antipsychotic olanzapine
11. Review of the preclinical pharmacology of olanzapine: A MARTA class antipsychotic
12. 1-adrenergic receptors in vitro
13. Olanzapine: A basic science update
14. 50) of an enzymatic reaction
15. 3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride
16. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer
17. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
18. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
19. Does metoclopramide supplement postoperative analgesia using patient-controlled analgesia with morphine in patients undergoing elective cesarean delivery?
20. 35S]guanosine-5′-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay
21. Block of the delayed rectifier current (IK) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes
22. 4) receptors
23. Efficacy and tolerability of topisetron in primary fibromyalgia - A highly selective and competitive 5-HT3 receptor antagonist
24. Irritable bowel syndrome: New pharmaceutical approaches to treatment
25. The classification of adrenoreceptors (adrenergic receptors): An evaluation from the standpoint of receptor theory
26. 35S]GTPgammaS binding assays
27. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications
28. 3 receptor antagonists
29. 6 serotonin receptor
30. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels
31. 3 receptor antagonist, in female irritable bowel syndrome in patients
32. Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation
33. Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation
34. New concepts of irritable bowel syndrome
35. Molecular cloning of human 5-hydroxytryptamine3 receptor: Heterogeneity in distribution and function among species
36. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs
37. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule
38. 3 receptor subtype in the rat brain and spinal cord
39. 4.4 receptors: Actions of antiparkinsonian and antipsychotic agents
40. Serotonin antagonists in the management of cisplatin-induced emesis
41. Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine
42. 3 receptor antagonist, in patients with irritable bowel syndrome
43. Neuropsychological change in early phase schizophrenia during 12 months treatment with olanzapine, risperidone or haloperidol
44. Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex
45. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs
46. 6 antagonist SB-271046
47. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
48. 6 receptor antagonist
49. Insufficient effectiveness of 5-hydroxytryptamine-3 receptor antagonists due to oral morphine administration in patients with cisplatin-induced emesis
50. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia
51. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma
52. Selective 5-hydroxytryptamine Type 3 receptor antagonism with ondansetron as treatment for diarrhea-prominent irritable bowel syndrome: A pilot study
53. Chiral recognition of the angiotensin II (T1) receptor by a highly potent phenoxyproline octanoamide
54. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized placebo-controlled trial
55. Olanzapine versus placebo in the treatment of acute mania
56. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
57. A double-blind controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia
58. Ondansetron treatment in patients with Tourette's syndrome
59. Association study of serotonin-6 variant (C267T) with schizophrenia and aggressive behavior
60. 6 receptor polymorphism C267T in Alzheimer's disease
61. 6) receptor gene in bipolar affective disorder and schizophrenia
62. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists
63. 6 receptor subtype in the rat brain